Pyrotinib

Generic Name: Pyrotinib

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₃₁ClN_₆O_₃

CAS Number: 1269662-73-8

Unique Ingredient Identifier: CJN36EQM0H

Background: Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Clinical Trials

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2023-04-28

Last Posted Date: 2023-04-28

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 188

Registration Number: NCT05834764

Locations: 🇨🇳
JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Inetetamab
Drug: Pyrotinib
Drug: Oral Vinorelbine Tartrate

First Posted Date: 2023-04-21

Last Posted Date: 2023-09-14

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 30

Registration Number: NCT05823623

Locations: 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Pyrotinib
Drug: Fulvestrant

First Posted Date: 2023-04-10

Last Posted Date: 2023-04-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT05806671

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, China

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: pyrotinib combined with trastuzumab, dalpiciclib and letrozole

First Posted Date: 2023-04-06

Last Posted Date: 2023-04-06

Lead Sponsor: Yantai Yuhuangding Hospital

Target Recruit Count: 30

Registration Number: NCT05800756

Locations: 🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2023-03-15

Last Posted Date: 2024-10-09

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 125

Registration Number: NCT05769010

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

Recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Inetetamab
Drug: Pyrotinib
Drug: Vinorelbine

First Posted Date: 2023-03-13

Last Posted Date: 2023-03-27

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 100

Registration Number: NCT05764941

Locations: 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2023-03-02

Last Posted Date: 2023-03-02

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 45

Registration Number: NCT05751018

Locations: 🇨🇳
Peking Union Medical College, Beijing, Beijing, China

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: RC48-ADC
Drug: Pyrotinib

First Posted Date: 2023-02-27

Last Posted Date: 2023-11-27

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT05745740

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Dalpiciclib
Drug: Docetaxel
Drug: Carboplatin
Drug: Letrozole
Drug: Gonadotropin-releasing hormone agonist

First Posted Date: 2022-12-06

Last Posted Date: 2023-03-20

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 236

Registration Number: NCT05638594

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: SHR-A1811
Drug: Pyrotinib

First Posted Date: 2022-12-02

Last Posted Date: 2024-07-05

Lead Sponsor: Shengjing Hospital

Target Recruit Count: 65

Registration Number: NCT05635487

Locations: 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy